Search Results - "Luzardo, Hugo"

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma by Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Corral, Lucía López, Morales, Rafael Hernani, Ortiz-Maldonado, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Domínguez, María Luisa Guerra, Pina, Jose Maria Sanchez, Mussetti, Alberto, Sancho, Juan Manuel, Bastos-Oreiro, Mariana, Catala, Eva, Delgado, Javier, Henriquez, Hugo Luzardo, Sanz, Jaime, Calbacho, María, Bailén, Rebeca, Carpio, Cecilia, Ribera, Jose Maria, Sureda, Anna, Briones, Javier, Hernandez-Boluda, Juan Carlos, Cebrián, Nuria Martínez, Martin, Jose Luis Diez, Martín, Alejandro, Barba, Pere

“…Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory…”
Get full text

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups by Bastos-Oreiro, Mariana, Gutierrez, Antonio, Reguera, Juan Luís, Iacoboni, Gloria, López-Corral, Lucía, Terol, María José, Ortíz-Maldonado, Valentín, Sanz, Jaime, Guerra-Dominguez, Luisa, Bailen, Rebeca, Mussetti, Alberto, Abrisqueta, Pau, Hernani, Rafael, Luzardo, Hugo, Sancho, Juan-Manuel, Delgado-Serrano, Javier, Salar, Antonio, Grande, Carlos, Bento, Leyre, González de Villambrosía, Sonia, García-Belmonte, Daniel, Sureda, Anna, Pérez-Martínez, Antonio, Barba, Pere, Kwon, Mi, Martín García-Sancho, Alejandro

“…Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory…”
Get full text

Extranodal natural killer/T‐cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets by Gonzalez Barca, Eva, Tomás‐Roca, Laura, Esteve, Anna, Rodriguez, Marta, Gato, Lucía, Alonso‐Alonso, Ruth, Martin Garcia‐Sancho, Alejandro, Cordoba, Raul, Monter‐Rovira, Anna, Bastos‐Oreiro, Mariana, Bergua Burgues, Juan Miguel, Sayas, Maria Jose, Viguria Alegria, Maria Cruz, Sanchez‐Blanco, Jose Javier, Roig Pellicer, Monica, Luzardo Henriquez, Hugo Daniel, Oña, Raquel, Cabezudo, Maria Elena, Infante, Maria Stefania, Queizán Hernández, José Antonio, Sanz‐Pamplona, Rebeca, Blanco, Oscar, Mozos, Ana, Climent, Fina, Piris, Miguel Angel

“…(A) Correlation matrix of unsupervised co‐regulated genes, based on the 208 genes included in the NanoString platform. Some of the clusters of co‐regulated…”
Get full text

RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group by Bastos-Oreiro, Mariana, Muntañola, Ana, Panizo, Carlos, Gonzalez-Barca, Eva, de Villambrosia, Sonia González, Córdoba, Raúl, López, Jose Luís Bello, González-Sierra, Pedro, Terol, María José, Gutierrez, Antonio, Grande, Carlos, Ramirez, María José, Iserte, Laura, Perez, Elena, Navarro, Belén, Gomez, Pilar, Salar, Antonio, Luzardo, Hugo, López, Andrés, Del Campo, Raquel, García-Belmonte, Daniel, Vida, María Jesús, Infante, María, Queizan-Hernandez, Jose Antonio, Novelli, Silvana, Moreno, Miriam, Penarrubia, Miriam, Gómez, Joaquín, Domingo, Abel, Donato, Eva, Viguria, María Cruz, López, Francisca, Rodriguez, María José, Pardal, Emilia, Noriega, Victor, Andreu, Rafael, Peñalver, Javier, Martín, Alejandro, Caballero, Dolores, López-Guillermo, Armando

“…Lymphomas are a large, heterogeneous group of neoplasms with well-defined characteristics, and this heterogeneity highlights the importance of epidemiological…”
Get full text

PB2329: ENTEROPATHY‐ASSOCIATED T‐CELL LYMPHOMA (EATL): MULTICENTRIC REVIEW OF CLINICAL FEATURES AND TREATMENT: ON BEHALF OF GELTAMO (GRUPO ESPAÑOL DE LINFOMAS Y TRASPLANTES DE MÉDULA ÓSEA) by Infante, Maria Stefania, Garcia‐Sancho, Alejandro Martin, Luzardo, Hugo, Gomez, Marta, Domènech, Eva Domingo

Get full text

Acute neurologic deterioration in a patient with asymptomatic Charcot-Marie-Tooth disease following three doses of Brentuximab-Vedotin by de la Nuez Melián, Haridian, Luzardo Henríquez, Hugo, Suárez Cabrera, Alexia, Stuckey, Ruth, Gómez-Casares, María Teresa

Get full text

The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia by Saez Perdomo, María Nieves, Stuckey, Ruth, González-Pérez, Elena, Sánchez-Sosa, Santiago, Estupiñan-Cabrera, Paula, Lakhwani Lakhwani, Sunil, González San Miguel, José David, Hernanz Soler, Nuria, Gordillo, Marina, González Brito, Gloria, Tapia-Torres, María, Ruano, Ana, Segura-Díaz, Adrián, Luzardo, Hugo, Bilbao-Sieyro, Cristina, Gómez-Casares, María Teresa

“…Second- and third-generation tyrosine kinase inhibitors (TKIs) are now available to treat chronic-phase chronic myeloid leukemia (CP-CML) in the first and…”
Get full text

New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group by Bastos‐Oreiro, Mariana, Abrisqueta, Pau, Gutierrez, Antonio, Jiménez Ubieto, Ana, Poza, Maria, Fernanez‐Caldas, Paula, LLacer, María José, Gonzalez de Villambrosia, Sonia, Córdoba, Raúl, López, Alberto, Ceballos, Elena, Navarro, Belen, Muntañola, Ana, Donato, Eva, Diez‐Baeza, Eva, Escoda, Lourdes, Luzardo, Hugo, Peñarrubia, María José, García Belmonte, Daniel, Pardal, Emilia, Lozada, Claudia, Martín García‐Sancho, Alejandro

Get full text

Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages by Suárez-Cabrera, Alexia, Fiallo-Suárez, Dolly Viviana, Stuckey, Ruth, Uroz-de la Iglesia, Marta Luna, Florido, Yanira, Lemes-Castellano, Angelina, Perera-Álvarez, Miguel Ángel, Luzardo-Henríquez, Hugo, de la Nuez, Haridian, Fernández-Caldas, Paula, de la Iglesia, Silvia, Gómez-Casares, María Teresa, Bilbao-Sieyro, Cristina

“…Chronic lymphocytic leukemia (CLL) has a variable clinical evolution, with some patients living treatment-free for decades while others require therapy shortly…”
Get full text

Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment by Iacoboni, Gloria, Navarro, Víctor, Sesques, Pierre, Rejeski, Kai, Bastos-Oreiro, Mariana, Serpenti, Fabio, Martin Lopez, Ana Africa, Iraola-Truchuelo, Josu, Delgado, Javier, Perez, Ariadna, Guerreiro, Manuel, Caballero, Ana Carolina, Martinez-Cibrian, Nuria, Luzardo Henriquez, Hugo, Sanchez Pina, Jose Maria, Sancho, Juan-Manuel, Ghesquieres, Hervé, Mussetti, Alberto, Lopez Corral, Lucia, Hernani, Rafael, Reguera, Juan Luis, Sureda, Anna, Bosch, Francesc, Martin Garcia-Sancho, Alejandro, Kwon, Mi, Subklewe, Marion, Kuhnl, Andrea, Bachy, Emmanuel, Barba, Pere, Villacampa, Guillermo, Abrisqueta, Pau

“…Chimeric antigen receptor (CAR) T-cell therapy fails to achieve durable responses in over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL)…”
Get full text

Positive Impact of Eculizumab Therapy on Surgery for Budd- Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Longterm History of Thrombosis by De-la-Iglesia, Silvia, Luzardo, Hugo, Lemes, Angelina, Torres, Melissa, Gómez-Casares, Maria Teresa, Cruz, Naylen, Molero, Teresa

“…Paroxysmal nocturnal hemoglobinuria (PNH) is associated with severe end-organ damage and a high risk of thrombosis. Budd- Chiari syndrome, which develops after…”
Get full text

Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma by Stuckey, Ruth, Luzardo Henríquez, Hugo, de la Nuez Melian, Haridian, Rivero Vera, José Carlos, Bilbao-Sieyro, Cristina, Gómez-Casares, María Teresa

“…Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the most common forms of aggressive and indolent lymphoma, respectively. The majority of…”
Get full text

New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO) by Bento, Leyre, Díaz‐López, Antonio, Barranco, Gilberto, Martín‐Moreno, Ana M., Baile, Mónica, Martín, Alejandro, Sancho, Juan M., García, Olga, Rodríguez, Mario, Sánchez‐Pina, Jose M., Novelli, Silvana, Salar, Antonio, Bastos, Mariana, Rodríguez‐Salazar, M José, González de Villambrosia, Sonia, Córdoba, Raul, García‐Recio, M., Martínez‐Serra, J., Campo, Raquel, Luzardo, Hugo, García, Daniel, Hong, Azueg, Abrisqueta, Pau, Sastre‐Serra, Jorge, Roca, Pilar, Rodríguez, José, Gutiérrez, Antonio

“…Summary The International Prognostic Index (IPI) is the most widely used score for non‐Hodgkin lymphoma but lacks the ability to identify a high‐risk…”
Get full text

Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial by Ribera, Josep-Maria, Morgades, Mireia, Garcia-Calduch, Olga, Sirvent, Maialen, Buendia, Buenaventura, Cervera, Marta, Luzardo, Hugo, Hernandez-Rivas, Jesus-Maria, Sitges, Marta, Garcia-Cadenas, Irene, Abrisqueta, Pau, Montesinos, Pau, Bastos-Oreiro, Mariana, De Llano, Maria-Paz Queipo, Bravo, Pilar, Torrent, Anna, Herrera, Pilar, Garcia-Guinon, Antoni, Vall-Llovera, Ferran, Serrano, Josefina, Terol, Maria-Jose, Bergua, Juan-Miguel, Garcia-Noblejas, Ana, Barrenetxea, Cristina, Llorente, Laura, Garcia-Belmonte, Daniel, Gimeno, Eva, Cladera, Antonia, Mercadal, Santiago, Sancho, Juan-Manuel

“…High dose-intensive or infusional intermediate-dose immunochemotherapy is highly effective treatment for Burkitt lymphoma irrespective of human…”
Get full text

Spontaneous remission after a year of romiplostim in an adult patient with refractory primary immune thrombocytopenia by Perera, Maria, Suarez, Alexia, Luzardo, Hugo, Lopez, Jezabel, Molero, Teresa

Get full text

Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO by Bailén, Rebeca, Iacoboni, Gloria, Delgado, Javier, López-Corral, Lucía, Hernani-Morales, Rafael, Ortiz-Maldonado, Valentín, Guerreiro, Manuel, Caballero, Ana Carolina, Guerra-Domínguez, María Luisa, Sánchez-Pina, Jose Maria, Peña, Marta, Torrent, Anna, Pérez-Martínez, Antonio, Bastos-Oreiro, Mariana, Reguera-Ortega, Juan Luis, Martín, Alejandro, Hernandez-Boluda, Juan Carlos, Martínez-Cibrián, Nuria, Sanz, Jaime, Briones, Javier, Henriquez, Hugo Luzardo, Calbacho, María, Mussetti, Alberto, Sancho, Juan Manuel, Barba, Pere, Kwon, Mi

“…•CAR-T cell therapy was safe and effective in elderly patients.•Response, OS and EFS in patients older and younger than 70 years were comparable.•Age ≥70 years…”
Get full text

Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study by Bastos-Oreiro, Mariana, Gutierrez, Antonio, Iacoboni, Gloria, López Corral, Lucía, Reguera, Juan Luis, Abrisqueta, Pau, Delgado, Javier, Terol, María José, Hernani, Rafael, Martínez, Nuria, Ortíz, Valentín, Bailen, Rebeca, Gomez-Centurión, Ignacio, Caballero, Ana, Sanz, Jaime, Guerra Domínguez, Luisa, Luzardo, Hugo, Mussetti, Alberto, Jiménez-Ubieto, Ana, Sancho, Juan Manuel, Sureda, Anna, Pérez, Antonio, Barba, Pere, Kwon, Mi, Martín García-Sancho, Alejandro

“…In the pre-chimeric antigen receptor T cell (CAR-T) therapy era, the SCHOLAR-1 study identified a group of patients with refractory aggressive B cell lymphoma…”
Get full text

Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era by Gutierrez, Antonio, Bento, Leyre, Diaz‐Lopez, Antonio, Barranco, Gilberto, Garcia‐Recio, Marta, Lopez‐Guillermo, Armando, Dlouhy, Ivan, Rovira, Jordina, Rodriguez, Mario, Sanchez Pina, Jose María, Baile, Monica, Martín, Alejandro, Novelli, Silvana, Sancho, Juan‐Manuel, García, Olga, Salar, Antonio, Bastos‐Oreiro, Mariana, Rodriguez‐Salazar, Mª José, Fernandez, Ruben, Cruz, Fatima, Queizan, Jose Antonio, González de Villambrosia, Sonia, Cordoba, Raul, López, Andres, Luzardo, Hugo, García, Daniel, Sastre‐Serra, Jordi, Garcia, Juan Fernando, Montalban, Carlos, Cabanillas, Fernando, Rodríguez, Jose

“…Objectives Diffuse large B‐cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%‐40% of patients still fail, so…”
Get full text

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy by Iacoboni, Gloria, Iraola‐Truchuelo, Josu, O'Reilly, Maeve, Navarro, Víctor, Menne, Tobias, Kwon, Mi, Martín‐López, Ana África, Chaganti, Sridhar, Delgado, Javier, Roddie, Claire, Pérez, Ariadna, Norman, Jane, Guerreiro, Manuel, Gibb, Adam, Caballero, Ana Carolina, Besley, Caroline, Martínez‐Cibrián, Nuria, Mussetti, Alberto, Sanderson, Robin, Luzardo, Hugo, Iyengar, Sunil, Sánchez, Jose Maria, Jones, Ceri, Sancho, Juan‐Manuel, Barba, Pere, Latif, Anne‐Louise, López‐Corral, Lucia, Hernani, Rafael, Reguera, Juan Luis, Sureda, Anna, Garcia‐Sancho, Alejandro Martin, Bastos, Mariana, Abrisqueta, Pau, Kuhnl, Andrea

“…Over 60% of relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease…”
Get full text

P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL by Maria Ribera, Josep, Morgades, Mireia, García‐Calduch, Olga, Sirvent, Maialen, Buendía Ureña, Buenaventura, Cervera, Marta, Luzardo, Hugo, Hernández Rivas, Jesus, Sitges Arriaga, Marta, Garcia Cadenas, Irene, Abrisquet Acosta, Pablo, Montesinos, Pau, Bastos Oreiro, Mariana, Queipo de Llano, María‐Paz, Bravo, Pilar, Torrent, Anna, Puente, Maria Pilar Herrera, Garcia‐Guiñon, Antonio, Vall‐Llovera Calmet, Ferran, Serrano, Josefina, Terol, Maria J, Burgues, Juan Miguel Bergua, García‐Noblejas, Ana, Barrenetxea, Cristina, Llorente, Laura, García‐Belmonte, Daniel, Gimeno, Eva, Cladera, Antonia, Mercadal Vilchez, Santiago, Manuel Sancho, Juan

Get full text